Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival.

Suidan AM, Roisman L, Belilovski Rozenblum A, Ilouze M, Dudnik E, Zer A, Peled N.

J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.18.00216. No abstract available.

2.

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).

Dudnik E, Bshara E, Grubstein A, Fridel L, Shochat T, Roisman LC, Ilouze M, Rozenblum AB, Geva S, Zer A, Rotem O, Allen AM, Peled N.

Lung Cancer. 2018 Oct;124:117-124. doi: 10.1016/j.lungcan.2018.07.044. Epub 2018 Aug 3.

PMID:
30268448
3.

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.

Laufer-Geva S, Rozenblum AB, Twito T, Grinberg R, Dvir A, Soussan-Gutman L, Ilouze M, Roisman LC, Dudnik E, Zer A, Rotem O, Lanman RB, Peled N.

J Thorac Oncol. 2018 Nov;13(11):1705-1716. doi: 10.1016/j.jtho.2018.07.101. Epub 2018 Aug 16.

PMID:
30121392
4.

Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.

Landman Y, Ilouze M, Wein S, Neiman V, Yerushalmi R, Yakimov M, Ku N, Schrock AB, Ali S, Peled N.

Clin Breast Cancer. 2018 Jun;18(3):e267-e270. doi: 10.1016/j.clbc.2017.11.017. Epub 2017 Nov 28. No abstract available.

PMID:
29233640
5.

[THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].

Belilovski Rozenblum A, Ilouze M, Dudnik E, Soussan-Gutman L, Dvir A, Peled N.

Harefuah. 2017 Nov;156(11):686-691. Hebrew.

PMID:
29198084
6.

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.

Shlomi D, Abud M, Liran O, Bar J, Gai-Mor N, Ilouze M, Onn A, Ben-Nun A, Haick H, Peled N.

J Thorac Oncol. 2017 Oct;12(10):1544-1551. doi: 10.1016/j.jtho.2017.06.073. Epub 2017 Jul 12.

7.

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y.

J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7. No abstract available.

8.

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.

Sarfaty M, Moore A, Neiman V, Dudnik E, Ilouze M, Gottfried M, Katznelson R, Nechushtan H, Sorotsky HG, Paz K, Katz A, Saute M, Wolner M, Moskovitz M, Miller V, Elvin J, Lipson D, Ali S, Gutman LS, Dvir A, Gordon N, Peled N.

Clin Lung Cancer. 2017 Jul;18(4):e223-e232. doi: 10.1016/j.cllc.2016.09.003. Epub 2016 Oct 29.

PMID:
28082048
9.

Cancer metabolism: the volatile signature of glycolysis-in vitro model in lung cancer cells.

Feinberg T, Herbig J, Kohl I, Las G, Cancilla JC, Torrecilla JS, Ilouze M, Haick H, Peled N.

J Breath Res. 2017 Jan 9;11(1):016008. doi: 10.1088/1752-7163/aa51d6.

PMID:
28068289
10.

Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.

Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.

J Thorac Oncol. 2017 Feb;12(2):258-268. doi: 10.1016/j.jtho.2016.10.021. Epub 2016 Nov 16.

11.

Cancerous glucose metabolism in lung cancer-evidence from exhaled breath analysis.

Feinberg T, Alkoby-Meshulam L, Herbig J, Cancilla JC, Torrecilla JS, Gai Mor N, Bar J, Ilouze M, Haick H, Peled N.

J Breath Res. 2016 Jun 7;10(2):026012. doi: 10.1088/1752-7155/10/2/026012.

PMID:
27272440
12.

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.

Nardi-Agmon I, Abud-Hawa M, Liran O, Gai-Mor N, Ilouze M, Onn A, Bar J, Shlomi D, Haick H, Peled N.

J Thorac Oncol. 2016 Jun;11(6):827-37. doi: 10.1016/j.jtho.2016.02.017. Epub 2016 Mar 9.

13.

Screening for Lung Cancer: What Comes Next?

Peled N, Ilouze M.

J Clin Oncol. 2015 Nov 20;33(33):3847-8. doi: 10.1200/JCO.2015.63.1713. Epub 2015 Aug 24. No abstract available.

PMID:
26304887
14.

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N.

Oncologist. 2015 Mar;20(3):316-22. doi: 10.1634/theoncologist.2014-0389. Epub 2015 Feb 26.

15.

Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short report.

Shavit R, Ilouze M, Feinberg T, Lawrence YR, Tzur Y, Peled N.

Cell Oncol (Dordr). 2015 Jun;38(3):247-52. doi: 10.1007/s13402-014-0212-6. Epub 2015 Jan 7.

PMID:
25563585
16.

Unique volatolomic signatures of TP53 and KRAS in lung cells.

Davies MP, Barash O, Jeries R, Peled N, Ilouze M, Hyde R, Marcus MW, Field JK, Haick H.

Br J Cancer. 2014 Sep 9;111(6):1213-21. doi: 10.1038/bjc.2014.411. Epub 2014 Jul 22.

17.

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038. No abstract available.

18.

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR.

Cell Oncol (Dordr). 2013 Jul;36(4):277-88. doi: 10.1007/s13402-013-0133-9. Epub 2013 Apr 26.

19.

Volatile fingerprints of cancer specific genetic mutations.

Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H.

Nanomedicine. 2013 Aug;9(6):758-66. doi: 10.1016/j.nano.2013.01.008. Epub 2013 Feb 18.

20.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, Soussan-Gutman L, Otto GA, Stephens PJ, Ross JS, Cronin MT, Lipson D, Miller VA.

J Thorac Oncol. 2012 Sep;7(9):e14-6. doi: 10.1097/JTO.0b013e3182614ab5. No abstract available.

21.

Down-regulation of the cyprinid herpesvirus-3 annotated genes in cultured cells maintained at restrictive high temperature.

Ilouze M, Dishon A, Kotler M.

Virus Res. 2012 Oct;169(1):289-95. doi: 10.1016/j.virusres.2012.07.013. Epub 2012 Jul 25.

PMID:
22841492
22.

Coordinated and sequential transcription of the cyprinid herpesvirus-3 annotated genes.

Ilouze M, Dishon A, Kotler M.

Virus Res. 2012 Oct;169(1):98-106. doi: 10.1016/j.virusres.2012.07.015. Epub 2012 Jul 24.

PMID:
22841491
23.

Antibody response and resistance of Cyprinus carpio immunized with cyprinid herpes virus 3 (CyHV-3).

Perelberg A, Ilouze M, Kotler M, Steinitz M.

Vaccine. 2008 Jul 4;26(29-30):3750-6. doi: 10.1016/j.vaccine.2008.04.057. Epub 2008 May 12.

PMID:
18534721
24.

Susceptibility of cyprinid cultured cells to cyprinid herpesvirus 3.

Davidovich M, Dishon A, Ilouze M, Kotler M.

Arch Virol. 2007;152(8):1541-6. Epub 2007 May 14.

PMID:
17497237
25.

Persistence of cyprinid herpesvirus 3 in infected cultured carp cells.

Dishon A, Davidovich M, Ilouze M, Kotler M.

J Virol. 2007 May;81(9):4828-36. Epub 2007 Feb 14.

26.

Cyprinid herpes virus-3 (CyHV-3) bears genes of genetically distant large DNA viruses.

Ilouze M, Dishon A, Kahan T, Kotler M.

FEBS Lett. 2006 Aug 7;580(18):4473-8. Epub 2006 Jul 14.

27.

Characterization of a novel virus causing a lethal disease in carp and koi.

Ilouze M, Dishon A, Kotler M.

Microbiol Mol Biol Rev. 2006 Mar;70(1):147-56. Review. Erratum in: Microbiol Mol Biol Rev. 2006 Sep;70(3):857.

28.

Detection of carp interstitial nephritis and gill necrosis virus in fish droppings.

Dishon A, Perelberg A, Bishara-Shieban J, Ilouze M, Davidovich M, Werker S, Kotler M.

Appl Environ Microbiol. 2005 Nov;71(11):7285-91.

29.

Description of an as yet unclassified DNA virus from diseased Cyprinus carpio species.

Hutoran M, Ronen A, Perelberg A, Ilouze M, Dishon A, Bejerano I, Chen N, Kotler M.

J Virol. 2005 Feb;79(4):1983-91.

Supplemental Content

Loading ...
Support Center